Mostrar el registro sencillo del ítem

dc.contributor.authorTrickey, Adam
dc.contributor.authorMay, Margaret T
dc.contributor.authorVehreschild, Janne
dc.contributor.authorObel, Niels
dc.contributor.authorGill, Michael John
dc.contributor.authorCrane, Heidi
dc.contributor.authorBoesecke, Christoph
dc.contributor.authorSamji, Hasina
dc.contributor.authorGrabar, Sophie
dc.contributor.authorCazanave, Charles
dc.contributor.authorCavassini, Matthias
dc.contributor.authorShepherd, Leah
dc.contributor.authord'Arminio Monforte, Antonella
dc.contributor.authorSmit, Colette
dc.contributor.authorSaag, Michael
dc.contributor.authorLampe, Fiona
dc.contributor.authorHernando Sebastian, Victoria 
dc.contributor.authorMontero, Marta
dc.contributor.authorZangerle, Robert
dc.contributor.authorJustice, Amy C
dc.contributor.authorSterling, Timothy
dc.contributor.authorMiro, Jose
dc.contributor.authorIngle, Suzanne
dc.contributor.authorSterne, Jonathan A C
dc.date.accessioned2018-12-17T14:01:31Z
dc.date.available2018-12-17T14:01:31Z
dc.date.issued2016-08-15
dc.identifier.citationPLoS One. 2016 Aug 15;11(8):e0160460.es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/6876
dc.description.abstractObjectives: To estimate mortality rates and prognostic factors in HIV-positive patients who started combination antiretroviral therapy between 1996-1999 and survived for more than ten years. Methods: We used data from 18 European and North American HIV cohort studies contributing to the Antiretroviral Therapy Cohort Collaboration. We followed up patients from ten years after start of combination antiretroviral therapy. We estimated overall and cause-specific mortality rate ratios for age, sex, transmission through injection drug use, AIDS, CD4 count and HIV-1 RNA. Results: During 50,593 person years 656/13,011 (5%) patients died. Older age, male sex, injecting drug use transmission, AIDS, and low CD4 count and detectable viral replication ten years after starting combination antiretroviral therapy were associated with higher subsequent mortality. CD4 count at ART start did not predict mortality in models adjusted for patient characteristics ten years after start of antiretroviral therapy. The most frequent causes of death (among 340 classified) were non-AIDS cancer, AIDS, cardiovascular, and liver-related disease. Older age was strongly associated with cardiovascular mortality, injecting drug use transmission with non-AIDS infection and liver-related mortality, and low CD4 and detectable viral replication ten years after starting antiretroviral therapy with AIDS mortality. Five-year mortality risk was <5% in 60% of all patients, and in 30% of those aged over 60 years. Conclusions: Viral replication, lower CD4 count, prior AIDS, and transmission via injecting drug use continue to predict higher all-cause and AIDS-related mortality in patients treated with combination antiretroviral therapy for over a decade. Deaths from AIDS and non-AIDS infection are less frequent than deaths from other non-AIDS causes.es_ES
dc.description.sponsorshipThis work was supported by the UK Medical Research Council (MRC) MR/J002380/1—http://www.mrc.ac.uk/— and the UK Department for International Development (DFID) under the MRC/DFID Concordat agreement and is also part of the EDCTP2 programme supported by the European Union.es_ES
dc.language.isoenges_ES
dc.publisherPublic Library of Science (PLOS) es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subject.meshAdolescent es_ES
dc.subject.meshAdult es_ES
dc.subject.meshAged es_ES
dc.subject.meshAnti-HIV Agents es_ES
dc.subject.meshDemography es_ES
dc.subject.meshFemale es_ES
dc.subject.meshHIV Infections es_ES
dc.subject.meshHIV-1 es_ES
dc.subject.meshHumans es_ES
dc.subject.meshMale es_ES
dc.subject.meshMiddle Aged es_ES
dc.subject.meshRisk Factors es_ES
dc.subject.meshSurvival Analysis es_ES
dc.subject.meshYoung Adult es_ES
dc.titleCause-Specific Mortality in HIV-Positive Patients Who Survived Ten Years after Starting Antiretroviral Therapyes_ES
dc.typeresearch articlees_ES
dc.rights.licenseAtribución- 4.0 Internacional*
dc.identifier.pubmedID27525413es_ES
dc.format.volume11es_ES
dc.format.number8es_ES
dc.format.pagee0160460es_ES
dc.identifier.doi10.1371/journal.pone.0160460es_ES
dc.contributor.funderMedical Research Council (Reino Unido) 
dc.contributor.funderDepartment for International Development (Reino Unido) 
dc.contributor.funderUnión Europea 
dc.description.peerreviewedes_ES
dc.identifier.e-issn1932-6203es_ES
dc.relation.publisherversionhttps://doi.org/10.1371/journal.pone.0160460es_ES
dc.identifier.journalPloS onees_ES
dc.repisalud.centroISCIII::Centro Nacional de Epidemiología
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsopen accesses_ES


Ficheros en el ítem

Acceso Abierto
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución- 4.0 Internacional
Este Item está sujeto a una licencia Creative Commons: Atribución- 4.0 Internacional